Jose Banchs
Concepts (254)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Echocardiography | 16 | 2021 | 591 | 3.760 |
Why?
| Heart Diseases | 12 | 2022 | 358 | 2.570 |
Why?
| Neoplasms | 22 | 2023 | 2235 | 2.420 |
Why?
| Echocardiography, Transesophageal | 4 | 2019 | 92 | 1.280 |
Why?
| Ventricular Function, Left | 7 | 2022 | 493 | 1.240 |
Why?
| Heart Ventricles | 7 | 2023 | 741 | 1.230 |
Why?
| Ventricular Dysfunction, Left | 7 | 2022 | 401 | 1.220 |
Why?
| Heart Neoplasms | 3 | 2018 | 51 | 1.050 |
Why?
| Cardiovascular Diseases | 8 | 2022 | 1859 | 1.040 |
Why?
| Anthracyclines | 5 | 2022 | 42 | 1.030 |
Why?
| Antineoplastic Agents | 10 | 2019 | 1990 | 1.000 |
Why?
| Atrial Flutter | 1 | 2023 | 28 | 0.910 |
Why?
| Cardiovascular System | 2 | 2023 | 132 | 0.850 |
Why?
| Atrial Fibrillation | 3 | 2023 | 392 | 0.830 |
Why?
| Stroke Volume | 7 | 2022 | 553 | 0.820 |
Why?
| Sarcoma | 3 | 2023 | 138 | 0.800 |
Why?
| Cardiology | 4 | 2020 | 338 | 0.770 |
Why?
| Medical Oncology | 5 | 2020 | 231 | 0.770 |
Why?
| Heart Function Tests | 2 | 2019 | 68 | 0.710 |
Why?
| Practice Patterns, Nurses' | 1 | 2018 | 15 | 0.660 |
Why?
| Osteosarcoma | 1 | 2019 | 70 | 0.650 |
Why?
| Thrombosis | 2 | 2018 | 319 | 0.640 |
Why?
| Endocarditis | 2 | 2021 | 36 | 0.620 |
Why?
| Thrombocytopenia | 1 | 2019 | 188 | 0.600 |
Why?
| Tachycardia, Sinus | 1 | 2016 | 1 | 0.600 |
Why?
| Diagnostic Imaging | 3 | 2018 | 310 | 0.580 |
Why?
| Pericardial Effusion | 4 | 2019 | 19 | 0.580 |
Why?
| Cardiotoxicity | 8 | 2023 | 33 | 0.570 |
Why?
| Echocardiography, Three-Dimensional | 2 | 2018 | 52 | 0.550 |
Why?
| Cardiomyopathies | 2 | 2016 | 308 | 0.540 |
Why?
| Education, Medical, Continuing | 1 | 2016 | 140 | 0.530 |
Why?
| Recovery of Function | 2 | 2016 | 610 | 0.530 |
Why?
| Takotsubo Cardiomyopathy | 1 | 2015 | 5 | 0.520 |
Why?
| Pericarditis | 1 | 2014 | 9 | 0.520 |
Why?
| Rural Population | 1 | 2018 | 482 | 0.500 |
Why?
| Fibroma | 1 | 2014 | 20 | 0.500 |
Why?
| Aortic Aneurysm | 1 | 2014 | 67 | 0.480 |
Why?
| Heart | 4 | 2023 | 649 | 0.480 |
Why?
| Radiotherapy | 1 | 2015 | 187 | 0.470 |
Why?
| Radiation Injuries | 1 | 2015 | 137 | 0.470 |
Why?
| Breast Neoplasms | 7 | 2022 | 1994 | 0.450 |
Why?
| Humans | 60 | 2023 | 122796 | 0.440 |
Why?
| Multimodal Imaging | 4 | 2018 | 102 | 0.440 |
Why?
| Cardiovascular Infections | 1 | 2012 | 2 | 0.430 |
Why?
| Heart Valve Prosthesis Implantation | 1 | 2014 | 191 | 0.420 |
Why?
| Tongue Neoplasms | 1 | 2012 | 21 | 0.420 |
Why?
| Vascular Diseases | 1 | 2015 | 251 | 0.410 |
Why?
| Cardiac Tamponade | 3 | 2016 | 16 | 0.410 |
Why?
| Tracheoesophageal Fistula | 1 | 2011 | 33 | 0.400 |
Why?
| Myocarditis | 1 | 2012 | 95 | 0.400 |
Why?
| Mass Screening | 1 | 2018 | 1095 | 0.390 |
Why?
| Fluoroscopy | 1 | 2011 | 149 | 0.390 |
Why?
| Radiography, Interventional | 1 | 2011 | 117 | 0.380 |
Why?
| Middle Aged | 23 | 2022 | 28563 | 0.380 |
Why?
| Ultrasonography, Interventional | 1 | 2011 | 156 | 0.370 |
Why?
| Trastuzumab | 5 | 2016 | 93 | 0.350 |
Why?
| Female | 32 | 2022 | 63629 | 0.340 |
Why?
| Quality Improvement | 1 | 2016 | 1004 | 0.340 |
Why?
| Male | 28 | 2022 | 59639 | 0.330 |
Why?
| Stents | 1 | 2011 | 491 | 0.310 |
Why?
| Early Diagnosis | 3 | 2018 | 242 | 0.300 |
Why?
| Coronary Artery Disease | 3 | 2021 | 695 | 0.290 |
Why?
| Heart Failure | 4 | 2023 | 2114 | 0.290 |
Why?
| Carcinoma, Squamous Cell | 1 | 2012 | 622 | 0.280 |
Why?
| Prognosis | 8 | 2023 | 3563 | 0.260 |
Why?
| Echocardiography, Doppler, Color | 2 | 2015 | 38 | 0.260 |
Why?
| Risk Factors | 11 | 2023 | 9381 | 0.260 |
Why?
| Heart Conduction System | 2 | 2015 | 88 | 0.250 |
Why?
| Troponin I | 3 | 2015 | 83 | 0.250 |
Why?
| Predictive Value of Tests | 8 | 2022 | 1947 | 0.250 |
Why?
| Esophageal Neoplasms | 2 | 2020 | 287 | 0.240 |
Why?
| Circulating MicroRNA | 1 | 2023 | 23 | 0.230 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2019 | 1402 | 0.230 |
Why?
| Lung Neoplasms | 4 | 2020 | 2216 | 0.230 |
Why?
| Retrospective Studies | 14 | 2022 | 13433 | 0.230 |
Why?
| Texas | 4 | 2021 | 195 | 0.220 |
Why?
| Fatal Outcome | 2 | 2015 | 299 | 0.220 |
Why?
| Biomarkers | 7 | 2023 | 3662 | 0.210 |
Why?
| Mitogen-Activated Protein Kinase 7 | 1 | 2021 | 14 | 0.210 |
Why?
| Electrocardiography | 2 | 2015 | 620 | 0.200 |
Why?
| Poly(ADP-ribose) Polymerases | 1 | 2021 | 88 | 0.200 |
Why?
| Doxorubicin | 3 | 2023 | 304 | 0.200 |
Why?
| Adult | 15 | 2022 | 32385 | 0.200 |
Why?
| Lymphoma, Large B-Cell, Diffuse | 1 | 2022 | 93 | 0.200 |
Why?
| Catheters, Indwelling | 1 | 2021 | 82 | 0.200 |
Why?
| Ultrasonography | 3 | 2015 | 740 | 0.190 |
Why?
| Radiation, Ionizing | 1 | 2020 | 74 | 0.190 |
Why?
| Aged | 12 | 2022 | 20495 | 0.190 |
Why?
| Ventricular Dysfunction, Right | 1 | 2023 | 232 | 0.180 |
Why?
| Graft vs Host Disease | 1 | 2021 | 219 | 0.180 |
Why?
| ROC Curve | 2 | 2021 | 494 | 0.180 |
Why?
| Carcinoma, Non-Small-Cell Lung | 2 | 2020 | 967 | 0.170 |
Why?
| Pericardiocentesis | 1 | 2019 | 10 | 0.170 |
Why?
| Shock, Septic | 1 | 2021 | 213 | 0.170 |
Why?
| Radiotherapy, Intensity-Modulated | 1 | 2020 | 128 | 0.170 |
Why?
| Erdheim-Chester Disease | 1 | 2018 | 5 | 0.170 |
Why?
| Systole | 2 | 2016 | 178 | 0.170 |
Why?
| Cardiac Imaging Techniques | 1 | 2018 | 21 | 0.170 |
Why?
| Myxoma | 1 | 2018 | 13 | 0.170 |
Why?
| Follow-Up Studies | 5 | 2021 | 4768 | 0.160 |
Why?
| Echocardiography, Doppler | 1 | 2018 | 105 | 0.160 |
Why?
| Carcinoid Heart Disease | 1 | 2017 | 1 | 0.160 |
Why?
| Staphylococcus aureus | 1 | 2021 | 400 | 0.150 |
Why?
| Staphylococcal Infections | 1 | 2021 | 348 | 0.150 |
Why?
| Multiple Myeloma | 1 | 2018 | 103 | 0.150 |
Why?
| MicroRNAs | 1 | 2023 | 661 | 0.150 |
Why?
| Antineoplastic Agents, Immunological | 1 | 2019 | 159 | 0.150 |
Why?
| Academies and Institutes | 1 | 2016 | 44 | 0.140 |
Why?
| Reproducibility of Results | 2 | 2016 | 2977 | 0.140 |
Why?
| Oligopeptides | 1 | 2018 | 255 | 0.140 |
Why?
| Pericarditis, Constrictive | 1 | 2016 | 3 | 0.140 |
Why?
| Hematopoietic Stem Cell Transplantation | 1 | 2021 | 543 | 0.140 |
Why?
| Myocardial Ischemia | 1 | 2018 | 267 | 0.140 |
Why?
| Antibodies, Monoclonal, Humanized | 3 | 2015 | 658 | 0.140 |
Why?
| Withholding Treatment | 1 | 2016 | 68 | 0.140 |
Why?
| Cardiotoxins | 1 | 2015 | 5 | 0.140 |
Why?
| Clinical Decision-Making | 1 | 2018 | 293 | 0.130 |
Why?
| Sepsis | 1 | 2021 | 546 | 0.130 |
Why?
| Cardiotonic Agents | 1 | 2016 | 133 | 0.130 |
Why?
| Thrombolytic Therapy | 1 | 2016 | 122 | 0.130 |
Why?
| Ventricular Dysfunction | 1 | 2015 | 14 | 0.130 |
Why?
| Pulmonary Surgical Procedures | 1 | 2014 | 8 | 0.130 |
Why?
| Daptomycin | 1 | 2014 | 21 | 0.130 |
Why?
| Cefazolin | 1 | 2014 | 20 | 0.130 |
Why?
| Pericardium | 1 | 2015 | 53 | 0.130 |
Why?
| Carotid Artery Diseases | 1 | 2015 | 61 | 0.130 |
Why?
| Comorbidity | 3 | 2019 | 1600 | 0.120 |
Why?
| Dexmedetomidine | 1 | 2014 | 58 | 0.120 |
Why?
| Chemotherapy, Adjuvant | 1 | 2015 | 369 | 0.120 |
Why?
| Pulmonary Embolism | 1 | 2016 | 190 | 0.120 |
Why?
| Amyloidosis | 1 | 2014 | 41 | 0.120 |
Why?
| Survival Rate | 4 | 2021 | 1810 | 0.120 |
Why?
| Postoperative Complications | 2 | 2015 | 2301 | 0.120 |
Why?
| Peroxidase | 1 | 2013 | 182 | 0.120 |
Why?
| Cardiopulmonary Resuscitation | 1 | 2016 | 232 | 0.110 |
Why?
| Chemoradiotherapy | 1 | 2014 | 201 | 0.110 |
Why?
| Hodgkin Disease | 1 | 2015 | 121 | 0.110 |
Why?
| Heart Valve Prosthesis | 1 | 2014 | 126 | 0.110 |
Why?
| Myocardium | 1 | 2018 | 982 | 0.110 |
Why?
| Coronary Vessels | 1 | 2015 | 237 | 0.110 |
Why?
| Fluorodeoxyglucose F18 | 1 | 2013 | 138 | 0.110 |
Why?
| Antibiotics, Antineoplastic | 2 | 2023 | 115 | 0.110 |
Why?
| Preoperative Care | 1 | 2015 | 342 | 0.110 |
Why?
| Radiopharmaceuticals | 1 | 2013 | 196 | 0.110 |
Why?
| Decision Trees | 1 | 2012 | 95 | 0.110 |
Why?
| Heart Arrest | 1 | 2016 | 305 | 0.110 |
Why?
| Incidence | 4 | 2021 | 2527 | 0.100 |
Why?
| Positron-Emission Tomography | 1 | 2013 | 308 | 0.100 |
Why?
| Antibiotic Prophylaxis | 1 | 2012 | 101 | 0.100 |
Why?
| Young Adult | 3 | 2019 | 11094 | 0.100 |
Why?
| Endocarditis, Bacterial | 1 | 2012 | 38 | 0.100 |
Why?
| Hypertension, Pulmonary | 1 | 2023 | 1900 | 0.100 |
Why?
| Cardiac Catheterization | 1 | 2015 | 577 | 0.100 |
Why?
| Aortic Valve | 1 | 2014 | 428 | 0.090 |
Why?
| Prosthesis Implantation | 1 | 2011 | 148 | 0.090 |
Why?
| Radiosurgery | 1 | 2013 | 323 | 0.090 |
Why?
| Combined Modality Therapy | 3 | 2018 | 1174 | 0.090 |
Why?
| Risk Assessment | 3 | 2018 | 3213 | 0.090 |
Why?
| Anti-Inflammatory Agents | 1 | 2012 | 469 | 0.080 |
Why?
| Treatment Outcome | 4 | 2018 | 9692 | 0.080 |
Why?
| Animals | 5 | 2023 | 34133 | 0.070 |
Why?
| Myocardial Infarction | 1 | 2015 | 1134 | 0.070 |
Why?
| Aged, 80 and over | 3 | 2015 | 6845 | 0.070 |
Why?
| Antiviral Agents | 1 | 2012 | 670 | 0.070 |
Why?
| Sensitivity and Specificity | 1 | 2011 | 1855 | 0.070 |
Why?
| Palliative Care | 1 | 2012 | 632 | 0.070 |
Why?
| Prevalence | 1 | 2011 | 2442 | 0.060 |
Why?
| Troponin | 1 | 2023 | 51 | 0.060 |
Why?
| Natriuretic Peptide, Brain | 2 | 2015 | 109 | 0.060 |
Why?
| Taxoids | 2 | 2013 | 98 | 0.060 |
Why?
| Adolescent | 2 | 2019 | 18948 | 0.060 |
Why?
| Anti-Bacterial Agents | 1 | 2012 | 1562 | 0.050 |
Why?
| Cell- and Tissue-Based Therapy | 1 | 2022 | 55 | 0.050 |
Why?
| Ribose | 1 | 2021 | 18 | 0.050 |
Why?
| Antigens, CD19 | 1 | 2022 | 108 | 0.050 |
Why?
| Cyclophosphamide | 1 | 2021 | 223 | 0.050 |
Why?
| Adenosine Diphosphate | 1 | 2021 | 89 | 0.050 |
Why?
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2021 | 40 | 0.050 |
Why?
| Feedback | 1 | 2021 | 155 | 0.050 |
Why?
| Tertiary Care Centers | 1 | 2021 | 125 | 0.050 |
Why?
| Ventricular Function, Right | 1 | 2023 | 262 | 0.050 |
Why?
| Pulmonary Circulation | 1 | 2023 | 455 | 0.050 |
Why?
| Immunotherapy, Adoptive | 1 | 2022 | 192 | 0.050 |
Why?
| United States | 4 | 2019 | 13272 | 0.050 |
Why?
| Radiotherapy Dosage | 1 | 2020 | 244 | 0.050 |
Why?
| Poly-ADP-Ribose Binding Proteins | 1 | 2019 | 27 | 0.050 |
Why?
| DNA Topoisomerases, Type II | 1 | 2019 | 45 | 0.040 |
Why?
| Immunocompromised Host | 1 | 2021 | 205 | 0.040 |
Why?
| Peptide Fragments | 2 | 2015 | 715 | 0.040 |
Why?
| Exercise Therapy | 1 | 2023 | 375 | 0.040 |
Why?
| Multivariate Analysis | 2 | 2014 | 1531 | 0.040 |
Why?
| Societies | 1 | 2018 | 42 | 0.040 |
Why?
| Hemangiosarcoma | 1 | 2018 | 20 | 0.040 |
Why?
| Positron Emission Tomography Computed Tomography | 1 | 2018 | 71 | 0.040 |
Why?
| Logistic Models | 2 | 2015 | 1995 | 0.040 |
Why?
| Receptors, Antigen, T-Cell | 1 | 2022 | 656 | 0.040 |
Why?
| DNA Damage | 1 | 2020 | 368 | 0.040 |
Why?
| Arterial Occlusive Diseases | 1 | 2018 | 81 | 0.040 |
Why?
| Reference Values | 1 | 2018 | 789 | 0.040 |
Why?
| Phosphorylation | 1 | 2021 | 1733 | 0.040 |
Why?
| Program Development | 1 | 2019 | 372 | 0.040 |
Why?
| Interprofessional Relations | 1 | 2019 | 271 | 0.040 |
Why?
| Molecular Targeted Therapy | 1 | 2019 | 361 | 0.040 |
Why?
| Prospective Studies | 2 | 2022 | 6704 | 0.040 |
Why?
| Practice Guidelines as Topic | 2 | 2014 | 1519 | 0.040 |
Why?
| Morbidity | 1 | 2017 | 309 | 0.040 |
Why?
| Mice | 2 | 2023 | 15888 | 0.030 |
Why?
| Mitochondria | 1 | 2021 | 809 | 0.030 |
Why?
| Cytokines | 1 | 2023 | 1928 | 0.030 |
Why?
| Galectin 3 | 1 | 2015 | 20 | 0.030 |
Why?
| Growth Differentiation Factor 15 | 1 | 2015 | 36 | 0.030 |
Why?
| Recurrence | 1 | 2018 | 998 | 0.030 |
Why?
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2015 | 70 | 0.030 |
Why?
| Breast | 1 | 2015 | 141 | 0.030 |
Why?
| Intraoperative Care | 1 | 2014 | 40 | 0.030 |
Why?
| Adrenergic alpha-2 Receptor Agonists | 1 | 2014 | 31 | 0.030 |
Why?
| Diastole | 1 | 2015 | 147 | 0.030 |
Why?
| Program Evaluation | 1 | 2019 | 880 | 0.030 |
Why?
| Biopsy | 1 | 2018 | 1090 | 0.030 |
Why?
| Global Health | 1 | 2017 | 352 | 0.030 |
Why?
| SEER Program | 1 | 2015 | 206 | 0.030 |
Why?
| Secondary Prevention | 1 | 2016 | 257 | 0.030 |
Why?
| Clinical Trials, Phase I as Topic | 1 | 2014 | 50 | 0.030 |
Why?
| Ohio | 1 | 2014 | 144 | 0.030 |
Why?
| Drug Monitoring | 1 | 2015 | 189 | 0.030 |
Why?
| Oxidative Stress | 1 | 2020 | 1204 | 0.030 |
Why?
| Europe | 1 | 2014 | 369 | 0.030 |
Why?
| Clinical Trials as Topic | 1 | 2018 | 985 | 0.030 |
Why?
| C-Reactive Protein | 1 | 2015 | 363 | 0.030 |
Why?
| Acute Disease | 1 | 2016 | 984 | 0.030 |
Why?
| Phenotype | 1 | 2021 | 3070 | 0.030 |
Why?
| Amyloid | 1 | 2014 | 89 | 0.030 |
Why?
| Anesthesia | 1 | 2014 | 122 | 0.030 |
Why?
| Interleukin-1 Receptor-Like 1 Protein | 1 | 2012 | 24 | 0.030 |
Why?
| Consensus | 1 | 2014 | 554 | 0.030 |
Why?
| Time Factors | 2 | 2013 | 6682 | 0.030 |
Why?
| Odds Ratio | 1 | 2015 | 1043 | 0.030 |
Why?
| Action Potentials | 1 | 2015 | 433 | 0.030 |
Why?
| Disease Management | 1 | 2016 | 591 | 0.030 |
Why?
| North America | 1 | 2012 | 271 | 0.030 |
Why?
| Neoplasm Staging | 1 | 2015 | 1234 | 0.030 |
Why?
| Kaplan-Meier Estimate | 1 | 2014 | 884 | 0.020 |
Why?
| Pilot Projects | 1 | 2016 | 1477 | 0.020 |
Why?
| Radiology | 1 | 2014 | 203 | 0.020 |
Why?
| Chi-Square Distribution | 1 | 2012 | 551 | 0.020 |
Why?
| Age Factors | 1 | 2018 | 3114 | 0.020 |
Why?
| Myocardial Contraction | 1 | 2012 | 339 | 0.020 |
Why?
| Societies, Medical | 1 | 2014 | 741 | 0.020 |
Why?
| Receptors, Cell Surface | 1 | 2012 | 368 | 0.020 |
Why?
| Patient Selection | 1 | 2014 | 717 | 0.020 |
Why?
| Longitudinal Studies | 1 | 2015 | 2599 | 0.020 |
Why?
| Magnetic Resonance Imaging | 1 | 2018 | 3264 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2015 | 4734 | 0.020 |
Why?
| Cohort Studies | 1 | 2013 | 5294 | 0.010 |
Why?
|
|
Banchs's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|